PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Pramlintide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Pramlintide is a synthetic analogue of human amylin; in a 52-week trial in 651 people with type 1 diabetes, mealtime pramlintide added to insulin lowered HbA1c by 0.29-0.34% more than placebo, with a small weight loss and transient nausea. · pmid:15498087

In 656 insulin-treated people with type 2 diabetes, pramlintide 120 micrograms twice daily lowered HbA1c by about 0.6% over a year, with weight loss against weight gain on placebo. · pmid:12610038

Identity

PubChem CID 70691388: Pramlintide, C171H267N51O53S2, 3949 g/mol. · pubchem:70691388

CAS registry number 151126-32-8. · pubchem:70691388

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Pramlintide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. (2003) · establishedAmylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. (2004) · established20032004

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Pramlintide yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. · pmid 12610038 · 2003
    • Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. · pmid 15498087 · 2004
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.